

2024

Catalog

promise
ADVANCED PROTEOMICS

SIL-mAbs

FOR TARGETED LC-MS QUANTIFICATION



The gold standard for robust and reliable quantitative LC-MS workflow

www.promise-proteomics.com | contact@promise-proteomics.com

SIL-MONOCLONAL ANTIBODIES

Promise Proteomics is a pioneer and an expert in the development of mass spectrometry-based quantification methods and in bioproduction of Stable Isotope Labelled monoclonal Antibodies (SIL-mAbs)

Why use our SIL-mAbs ?

A stable isotope labelled (SIL) form of an analyte protein is widely regarded as the optimal internal standard¹ for absolute quantification of proteins using LC-MS.

SIL-mAbs correct bias (due to losses, incomplete digestion, adsorption, proteolysis...) occurring during the preparation and analytical workflow. With SIL-mAbs, the accuracy and reproducibility of your quantification data is improved.


This product is useful for :

- Bioanalysis pharmacokinetics studies (clinical & nonclinical),
- Research and Discovery/pre-clinical/clinical drug development

Characteristics

- Full length recombinant monoclonal antibodies
- High isotopic incorporation (>98%) and purity (>95%)
- Labelling on Arg, Lys residues, ¹³C ¹⁵N isotope
- Expression systems CHO or HEK

How to use it ?



Unlike the use of SIL-peptides, Promise's SIL-mAbs are processed along with the target analytes throughout the pre-analytical and LC-MS workflow thus improving robustness and quality of the quantitative data.

1. Todoroki, K. *et al.* (2020, février). Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates : A review of recent advances and future perspectives. *Journal of Pharmaceutical and Biomedical Analysis*, 179, 112991. <https://doi.org/10.1016/j.jpba.2019.112991>

OFF-THE-SHELF PRODUCTS

SIL-mAbs* are available to support your studies and clinical trials

SIL mAbs	REFERENCE	SIL mAbs	REFERENCE
Abatacept	ORF90261	Infliximab	REX08151
Adalimumab	HUU05211	Inotuzumab	INZ13241
Aflibercept	AFF90271	Ipilimumab	YEH92271
Alemtuzumab	ALZ10131	Ixekizumab	TAZ13261
Avelumab	BAH92571	Mirikizumab	OMZ13191
Belatacept	upon request	Natalizumab	coming soon
Bevacizumab	AVZ10161	Nivolumab	OPH95701
Brentuximab	coming soon	Obinutuzumab	GAH92161
Cemiplimab	coming soon	Ocrelizumab	OCZ10231
Cetuximab	ERX08221	Patritumab	coming soon
Concizumab	COZ13241	Pembrolizumab	KEH95331
Daratumumab	DAU05201	Pertuzumab	PEZ10191
Datopotamab	coming soon	Risankizumab	SKZ10121
Dinutuximab	DIX08251	Rituximab	RIX08221
Dupilumab	DUU08301	Sacituzumab	coming soon
Durvalumab	IMU05501	Secukinumab	COH92201
Eculizumab	SOZ11141	Siltuximab	SYX08151
Emicizumab	HEH95561	Tocilizumab	ACH92241
Epcoritamab	EPZ10171	Trastuzumab	HEZ10231
Etanercept	ENF90251	Ustekinumab	STU05261
Golimumab	SIU05281	Vedolizumab	ENZ10211
Guselkumab	TRU05271		

**for Research Use Only*

Is your SIL-mAb of interest not listed?

For 10 years, Promise Proteomics offers
customized bioproduction options.

Contact us for further information.



 contact@promise-proteomics.com

REFERENCES

Peer reviewed publications using our SIL-mAbs

- **University Medical Center Utrecht**

Smeijsters, E. H. E. *et al.* (2023). Optimization of a quantitative Anti-Drug Antibodies against Infliximab assay with the liquid Chromatography-Tandem Mass Spectrometry : A Method Validation Study and Future Perspectives. *Pharmaceutics*, 15(5), 1477. <https://doi.org/10.3390/pharmaceutics15051477>

- **University Medical Center Utrecht**

el Amrani, M. *et al.* (2019). Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry : Infliximab as proof of principle. *Journal of Translational Autoimmunity*, 1, 100004. <https://doi.org/10.1016/j.jtauto.2019.100004>

- **Hospices Civils de Lyon**

Millet, A. *et al.* (2019). Determination of Cetuximab in Plasma by Liquid Chromatography–High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled ¹³C,¹⁵N-Cetuximab Internal Standard. *Therapeutic Drug Monitoring*, 41(4), 467-475. <https://doi.org/10.1097/ftd.0000000000000613>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2018). Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry. *Therapeutic Drug Monitoring*, 40(4), 417-424. <https://doi.org/10.1097/ftd.0000000000000514>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2016). Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry : towards a standardization of the methods ? *Analytical and Bioanalytical Chemistry*, 409(5), 1195-1205. <https://doi.org/10.1007/s00216-016-0045-4>

- **University Medical Center Utrecht**

el Amrani, M. *et al.* (2016). Quantification of active infliximab in human serum with liquid chromatography–tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard : A target-based, sensitive and cost-effective method. *Journal of Chromatography A*, 1454, 42-48. <https://doi.org/10.1016/j.chroma.2016.05.070>